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Acquired sensory neuronopathies encompass a group of paraneoplastic, dysimmune, toxic or idiopathic disorders characterized
by degeneration of peripheral sensory neurons in dorsal root ganglia. As dorsal root ganglia cannot easily be explored, the
clinical diagnosis of these disorders may be difﬁcult. The question as to whether there exists a common clinical pattern of
sensory neuronopathies, allowing the establishment of validated and easy-to-use diagnostic criteria, has not yet been addressed.
In this study, logistic regression was used to construct diagnostic criteria on a retrospective study population of 78 patients with
sensory neuronopathies and 56 with other sensory neuropathies. For this, sensory neuronopathy was provisionally considered as
unambiguous in 44 patients with paraneoplastic disorder or cisplatin treatment and likely in 34 with a dysimmune or idiopathic
setting who may theoretically have another form of neuropathy. To test the homogeneity of the sensory neuronopathy popula-
tion, likely candidates were compared with unambiguous cases and then the whole population was compared with the other
sensory neuropathies population. Criteria accuracy was checked on 37 prospective patients referred for diagnosis of sensory
neuropathy. In the study population, sensory neuronopathy showed a common clinical and electrophysiological pattern that was
independent of the underlying cause, including unusual forms with only patchy sensory loss, mild electrical motor nerve
abnormalities and predominant small ﬁbre or isolated lower limb involvement. Logistic regression allowed the construction
of a set of criteria that gave fair results with the following combination: ataxia in the lower or upper limbs+asymmetrical
distribution+sensory loss not restricted to the lower limbs+at least one sensory action potential absent or three sensory action
potentials530% of the lower limit of normal in the upper limbs + less than two nerves with abnormal motor nerve conduction
study in the lower limbs.
Keywords: sensory neuronopathy; sensory ganglionopathy; sensory neuropathy; paraneoplastic neurological syndrome; cisplatin
Abbreviations: CSF=cerebrospinal ﬂuid; ENMG=electroneuromyographic study; ROC=receiver operator characteristic;
SAP=sensory action potentials; SNN=sensory neuronopathies
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Acquired sensory neuronopathies (SNN) or ganglionopathies
encompass different disorders characterized by a primary degen-
eration of sensory neurons in dorsal root ganglia (Kuntzer et al.,
2004; Sghirlanzoni et al., 2005). This has been pathologically
demonstrated with paraneoplastic SNN (Graus et al., 1990;
Dalmau et al., 1991; Wanschitz et al., 1997), HIV infection
(Scaravilli et al., 1992; Esiri et al., 1993), Sjo ¨gren’s syndrome,
unclassiﬁed connective diseases and rare idiopathic cases
(Okajima et al., 1983; Sobue et al., 1988; Grifﬁn et al., 1990;
Hainfellner et al., 1996; Kurokawa et al., 1998; Colli et al.,
2008). Interestingly, in all of these circumstances, dorsal root
ganglia degeneration was associated with an inﬂammatory T-cell
reaction suggesting that the disorder is mainly driven by a cell-
mediated immune response. That sensory neuron cell body is
the target of cisplatin toxicity is also recognized (Gill and
Windebank, 1998; Krarup-Hansen et al., 2007). Conversely,
with vitamin B6 toxicity (Windebank, 1985; Xu et al., 1989) or
anti-disialosyl antibodies (Kusunoki et al., 1996), the demonstra-
tion of dorsal root ganglia involvement relies on animal models
only. Finally, recent reports suggest that a variety of pure small
ﬁbre neuropathy may depend on a ganglionopathy, but this
has not yet been demonstrated by dorsal root ganglia
examination (Mori et al., 2003; Brannagan et al., 2005; Gibbons
et al., 2008).
Differentiating SNN from other sensory neuropathies is
important owing to the possibility of detecting disorders that
may beneﬁt from speciﬁc investigations and treatments.
However, this is difﬁcult in the absence of methods that allow
easy and non-traumatic exploration of dorsal root ganglia. In
addition, several conditions associated with SNN such as
Sjo ¨gren’s syndrome are not speciﬁcally connected with a gang-
lionopathy, as they also occur with other forms of neuropathy.
Lastly, there is evidence that both dorsal root ganglia and
peripheral nerves can simultaneously be affected in the same
patient. This explains why some authors maintain descriptive
terminologies such as ataxic sensory neuropathy or even sensory
neuropathy (Dalakas, 1986; Windebank et al., 1990). Hence,
there is a need for diagnostic criteria for SNN that can easily be
used in general practice. Several years ago, Asbury (Asbury, 1987;
Asbury and Brown, 1990) proposed that a non-length-dependent
distribution of sensory loss and an almost pure and severe
electrophysiological sensory involvement are distinctive of SNN.
Speciﬁc criteria have also been proposed for paraneoplastic
cases (Graus et al., 2004). Recently, skin biopsy has been
used to demonstrate non length-dependence of small ﬁbre loss
(Lauria et al., 2001) and spinal cord MRI to show degeneration
of the central process of large sensory neurons (Lauria et al.,
2000). Although universally used, Asbury’s criteria have
not been validated and do not take into account several
questions: is there a uniform pattern of acquired SNN? What
is the sensitivity and speciﬁcity of the proposed criteria? Can
different easy-to-use criteria differentiate SNN from other sensory
neuropathies? We addressed these questions in a case–control
study.
Materials and Methods
Patient selection
Patients consisted of two populations, the study and the test
population.
The study population was used for the construction of diagnostic
criteria. For this, we retrospectively reviewed the ﬁles of 85 patients
with paraneoplastic neurological disorders and 511 with sensory
non-paraneoplastic neuropathy referred between January 1993 and
January 2007 to the Rho ˆne-Alpes Reference Centre for Rare
Neuromuscular Diseases. To be selected for the study, patients
had to present a clinically pure sensory neuropathy even though
electrophysiological investigations may have shown motor nerve con-
duction study abnormalities, and a complete and detailed record of
the clinical and electrophysiological investigations had to be available.
All of the patients had to have been examined by one of us and to
have received a biological check-up with a search for at least diabetes
mellitus, renal failure, abnormal white blood cell count, plasma ion
abnormalities, monoclonal (M) gammopathy, liver perturbations, B12
deﬁciency, thyroid hormone abnormalities, well-characterized onco-
neural antibodies and organ- and non-organ-speciﬁc antibodies.
Patients with multiple causes of neuropathy, clinical radiculopathy,
entrapment neuropathy or hereditary neuropathy were excluded.
The study population consisted of two groups:
– SNN patients were provisionally classiﬁed as having unambigu-
ous or likely SNN. Unambiguous SNN included deﬁnite paraneo-
plastic SNN according to the PNS Euronetwork criteria (Graus
et al., 2004) and acute or subacute sensory neuropathy due to
cisplatin toxicity. SNN was considered likely by the clinician of
the reference centre in the absence of gold standard criteria in
those patients presenting with a clinically pure sensory neuropa-
thy with a non-length dependent distribution and pure or pre-
dominant sensory abnormalities on the nerve conduction study
independently of the associated context according to Asbury’s
criteria. The rationale for this classiﬁcation relies on the fact that
in the unambiguous group there was no alternative diagnosis for
the neuropathy, and a fair demonstration of dorsal root ganglia
involvement exists in the literature while in the likely group
several mechanisms of neuropathy were theoretically possible
for a given aetiology as it is the case with Sjo ¨gren’s syndrome,
unspeciﬁc dysimmune or idiopathic disorders.
– Controls were used as a reference population for the elaboration
of diagnostic criteria by comparison with patients with unambig-
uous or likely SNN. They consisted of patients with a clinically
pure sensory neuropathy and either a length-dependent distribu-
tion, or an etiological context or electrophysiological pattern
that clearly excluded SNN. They were a priori selected among
our population of patients with sensory neuropathy to represent
the largest possible panel of neuropathies of different origins and
patterns, whatever the actual relative frequency of each of these
neuropathies in the population.
The test population was an external group used for the validation of
diagnostic criteria established on the study population. It consisted of
37 unselected consecutive patients prospectively investigated in our
centre for the diagnosis of a pure sensory neuropathy between
January 2007 and June 2008. In the test population, the selected
models were compared with the ﬁnal diagnosis of the clinician taken
as an expert centre diagnosis.
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The following data were recorded and analysed for the study: sex and
age; clinical information including: at disease onset, modalities of onset
(acute 41 month; subacute 41 month and 46 months; progressive
46 months), presence of paresthesia/dysesthesia, ataxia, pain, ﬁrst
involvement in the lower, upper or four limbs; at maximum develop-
ment of the neuropathy: topography of sensory loss in the four limbs
(proximal or distal), face or trunk, presence of pain, dysesthesia/
paresthesia, ataxia in the upper or lower limbs, small (thermal and
pin-prink sensation) or large (vibration and joint position sense) ﬁbre
involvement, number of elicited tendon reﬂexes, symmetry or asym-
metry of the sensory loss, modiﬁed Rankin score, autonomic system
abnormalities including orthostatic hypotension, constipation or
diarrhoea, sexual impotence, bladder disturbances, abnormal sweating
and pupil abnormalities. In addition, the distribution of sensory
involvement was classiﬁed as consistent or not with a length-
dependent pattern. For this, limbs were segmented into six sections
from distal to proximal and the trunk into two vertical anterior and
posterior sections. Criteria for a length-dependent distribution were as
reported (Thomas and Ochoa, 1993). Cerebrospinal ﬂuid (CSF)
analysis abnormalities included protein concentration 40.5g/l, white
cell count 41/mm
3 or oligoclonal pattern.
For the electrophysiological study, conduction velocities were
recorded at full development of the neuropathy with classical proce-
dure in median, ulnar and radial nerves in the forearm and peroneal,
tibial, superﬁcial peroneal and sural nerves in the leg. Sensory action
potentials (SAP) were recorded with an orthodromic procedure
for median, ulnar and radial nerves, antidromically in the superﬁcial
peroneal and sural nerves and expressed as a percentage of the lower
limit of the laboratory normal value. Motor distal latencies, compound
muscle action potential and minimal F-wave latencies were recorded
for median, ulnar, tibial and peroneal nerves. The pattern of each
motor nerve was classiﬁed as normal, axonal/neuronal, demyelinating
or intermediate according to published criteria (Camdessanche et al.,
2002). To compare action potentials, conduction velocities and distal
and F wave latencies, the worst value of the right or left recorded
nerve was kept. Several dichotomized electrophysiological criteria were
tested including the presence of at least one, two or three abolished
SAP or SAP530% of lower limit of normal of the laboratory and one,
two or three motor nerve with abnormal nerve conduction study in
the upper or lower limbs. MRIs were analysed for the presence of
spinal cord T2 high signal and somatosensory evoked potentials
(SEPs) were evaluated for the presence of an involvement of the
peripheral and central pathway. Superﬁcial peroneal or radial
nerve biopsy were analysed on semithin sections for the estimation
of myelinated ﬁbre density, presence of demyelination, remyelination,
wallerian degeneration or regenerating clusters and on parafﬁn
embedded sections stained with H&S and by immunohistochemistry
with an anti-T3 antibody (Dako, Glostrup, Denmark) for the detection
of inﬂammatory T lymphocytes.
Statistical analysis
First, to test the homogeneity of SNN patients, we compared the
unambiguous and likely SNN groups with respect to demographic,
clinical, electrophysiological and biological data. Differences were
determined using the Fisher exact test for qualitative data and
Students t-test or Wilcoxon Mann–Whitney test for quantitative data.
Second, SNN patients (unambiguous and likely) were compared with
controls as previously. Areas under receiver operator characteristic
(ROC) curves were used to determine thresholds of sensory nerve
conduction studies differentiating SNN from controls. Sensitivity and
speciﬁcity were estimated for each of 85 items analysed using controls
as the reference group. When related to a test procedure, sensitivity is
deﬁned as the probability of correctly detecting a condition which
is present while speciﬁcity is the probability of failing to detect the
condition when it is indeed absent. Likelihood ratios for positive
(sensitivity divided by 1—speciﬁcity) and negative (1—sensitivity
divided by speciﬁcity) test results were computed to evaluate the
relative clinical utility of each item. Likelihood ratios above 10 and
below 0.1 were considered to provide strong evidence to rule in or
rule out diagnosis, respectively.
Third, logistic regression was used to construct multivariable models
to identify the association of variables that may discriminate the
SNN group from controls with the best accuracy in which each
selected variable was weighted according to the logistic regression
coefﬁcient. Goodness-of-ﬁt was evaluated using the Hosmer–
Lemeshow test. Areas under ROC curves (AURC) + 95% conﬁdence
interval were computed as a measure of the overall discrimination and
to determine the cut-off value separating patients as having or not
having SNN. We ﬁrst tested the Asbury’s and PNSEuronet group criteria
and then tried several a priori constructed models by introducing in
block in the logistic regression either the items included in the aforesaid
criteria or different combinations of items having the best likelihood
ratios. Finally, to select the best discriminative model, we performed a
stepwise logistic regression with all the clinical and electrophysiological
items recorded at onset or maximum development of the neuropathy
and having the best likelihood ratio+ or likelihood ratio–.
The validity of the models selected on the study population
was then evaluated in two ways. First, the ‘jackknife’ method was
performed on the study population and the results were presented
as correct classiﬁcation deﬁned as the fraction of patients and controls,
who were correctly classiﬁed. The jackknife method is a statistical
cross-validation technique in which one patient is removed and the
rule is rederived and used to classify the excluded patient (Efron, 1982;
Wasson et al., 1985). The patient’s predicted state is then compared
with the reference state. This process is repeated systematically for
each patient to determine the frequency with which the excluded
patient is correctly or incorrectly classiﬁed.
Second, models were tested on the external prospective test
population. In this population, the clinician diagnosis was made blindly
to this model approach. The number and percentage of patients well
classiﬁed using the diagnostic ﬁnal model compared with the clinician
diagnosis were computed, and sensitivity, speciﬁcity and likelihood
ratio+ were derived. Statistics were performed using SPSS TM
14.0 software.
Results
Patients and controls
In the retrospective study population, 78 patients were in the
SNN group (mean age 58 years, male 59%). Forty-four had an
unambiguous diagnosis of SNN with an acute or subacute sensory
neuropathy due to cisplatin toxicity in 11 cases and a deﬁnite
paraneoplastic SNN in 33 cases (30 anti-Hu and one anti-
amphiphysin antibody) (Fig. 1). SNN was considered as likely
in 34 patients. A dysimmune context occurred in 11 patients
including detection of anti-nuclear, SSA or mitochondria anti-
bodies, lupus anticoagulant, positive salivary gland biopsy or M
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was diagnosed in three of them. One patient had HIV infection.
In 22 patients with a negative diagnosis workup, SNN was
considered as idiopathic.
The control group consisted of 56 patients with clinical sensory
neuropathy (mean age 62 years, male gender 57%). The
neuropathy was dysimmune in 16: three had a chronic inﬂam-
matory demyelinating polyneuropathy, one the Lewis and
Sumner syndrome, one an acute inﬂammatory demyelinating
polyneuropathy, seven a distal demyelinating sensory neuropathy
with anti-MAG M IgM, one a chronic ataxic neuropathy with
anti-disialosyl M IgM, two mononeuritis multiplex with vasculitis
and one Sjo ¨gren’s syndrome. A metabolic neuropathy occurred in
10 patients including diabetes mellitus (4), B12 deﬁciency (4),
amyloidosis (1) and hypothyroidism (1). The neuropathy was
toxic in six patients: two alcoholic and four treatment-induced tox-
icity other than cisplatin. Finally, 24 patients had an axonal neuro-
pathy of unknown origin. The diagnosis of Lewis and Sumner
syndrome was retained in patients with a clinically pure multifocal
sensory presentation on the presence on the electroneuromyo-
graphic study (ENMG) of signs of multifocal motor nerve demyeli-
nation and that of mononeuritis multiplex on ENMG signs of motor
axonal degeneration and nerve biopsy ﬁndings of vasculitis.
The prospective test population consisted of 37 patients with
clinically pure sensory neuropathy (mean age 60.7 years, male
gender 70%). The ﬁnal diagnosis before evaluation of the criteria
was unambiguous SNN in one patient with onconeural antibody
and likely SNN in eight patients. Three additional patients were
suspected to have SNN but this diagnosis could not be deﬁnitively
retained because of borderline clinical or ENMG data. The other
patients had chronic inﬂammatory demyelinating polyneuropathy
(4), Lewis-Sumner syndrome (2), amyloidosis (1), diabetes mellitus
(1), B12 deﬁciency (1), alcoholic neuropathy (2), neuropathy with M
gammopathy (1), small ﬁbre neuropathy (1), neuropathy associated
with heart graft (1) or neuropathy of unknown origin (11).
Comparison of unambiguous versus
likely SNN
Results are summarized in Table 1. At full development, there was
no signiﬁcant difference in term of distribution, topography and
quality of sensory involvement between the two groups.
Characteristics that were shared by 480% of patients were the
topography of sensory abnormalities involving the distal part of
the four limbs, a non-length-dependent distribution, and presence
of paraesthesia. Ataxia in the upper or lower limbs occurred in 71%
of cases, small ﬁbre involvement in 62% and pain in 50%.
Asymmetrical distribution was present in 42% of patients. Rare par-
ticular clinical patterns that were not speciﬁc of one subgroup of
SNN included: pure upper limb or lower limb involvement, sensory
loss restricted to small ﬁbres and multifocal distribution of patchy
sensory loss that may be suggestive of mononeuritis multiplex.
Signiﬁcant clinical differences only occurred during the neurop-
athy onset. Usually, in possible SNN, onset was progressive and
Retrospective  
study 
Eligible patients  
n=596  
Not included 518 
(Selection criteria 
 or incomplete data) 
Pure clinical  
sensory neuropathy 
n=134 
Unambiguous or 
likely sensory  
neuronopathy 
n=78
Final clinical diagnosis 
Other  
neuropathy 
n = 56 
Elaboration of      
Diagnostic criteria        
Sensory  
neuronopathy 
n=64 
Other 
neuropathy 
n = 14 
Sensory  
neuronopathy 
n=5 
Other 
neuropathy 
n = 51 
jackkinife 
Prospective study 
Pure clinical  
sensory neuropathy 
Eligible patients 
n=37
Sensory  
neuronopathy 
n=11
Other 
neuropathy 
n = 1 
Sensory  
neuronopathy 
n=0
Other 
neuropathy 
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Diagnostic criteria 
Sensory  
neuronopathy 
n=12*
Final clinical diagnosis 
Other  
neuropathy 
n = 25 
Figure 1 Flow chart of the study design. Asterisk represents nine patients with SNN and three with suspected SNN. The diagnostic
criteria applied to both the study and test populations is Model 6 selected by the logistic regression.
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acute/subacute and more frequently affected the upper limbs
or the four limbs.
The electrophysiological study also demonstrated a similar pattern
in the two subgroups. There were no signiﬁcant differences in term
of sensory abnormalities. The number of abolished SAP and the
mean SAP amplitudes were similar in the four limbs. Concerning
motor nerve conduction studies, abnormalities were signiﬁcantly
more frequent in the lower limbs in patients with paraneoplastic
SNN consisting mostly of an axonal or intermediate pattern.
CSF examination was performed in 48 patients (3 cisplatin,
24 paraneoplastic and 21 likely SNN). It was signiﬁcantly abnormal
in patients with paraneoplastic SNN with a more frequent raised
protein level and oligoclonal pattern. Twenty-two patients under-
went spinal cord MRI (4 cisplatin, 2 paraneoplastic and 16 likely
SNN). It showed abnormal high signal of the posterior column in
only one of them. SEPs were studied in 25 patients (5 paraneo-
plastic, 2 cisplatin and 18 likely). They were not recordable in ﬁve
and showed a clear involvement of both the peripheral and central
process in seven. The last 13 patients had a severe peripheral
involvement preventing any valuable recording of the central
pathway.
Nerve biopsy was obtained in 16 patients, eight paraneoplastic
and eight non-paraneoplastic (dysimmune or idiopathic) SNN.
There were no differences concerning myelinated ﬁbre density
and morphological ﬁbre changes between paraneoplastic and
non-paraneoplastic SNN. Fibre loss was universal with a proportion
of ﬁbre undergoing axonal degeneration varying from 0% to 4%.
Occasional regenerating clusters were encountered in one case
of each group. One patient with dysimmune SNN had T-cell
inﬂammatory inﬁltrates around epineurial blood vessels.
Comparison of SNN versus control
sensory neuropathies
As unambiguous and likely SNN showed only few differences
concerning clinical and electrophysiological presentation, data of
the whole SNN population and controls were compared. Results
are summarized in Table 2. Comparatively to SNN, controls had a
neuropathy signiﬁcantly restricted to the lower limbs, especially
the distal part, with a symmetrical distribution. If the trunk
was equally involved in both groups, controls did not show
facial involvement. Ataxia and large sensory ﬁbre involvement or
autonomic perturbations were rarer. From the electrophysiological
point of view, in the SNN group, motor nerve conduction was less
severely altered in the four limbs. SAP amplitude was more
severely reduced in the median, ulnar and radial nerves, and
abolished SAP were more frequent in the upper limbs, but there
was no difference in the lower limbs. ROC curves analysis of SAP
amplitude expressed as a percentage of the lower limit of normal
showed that it was not possible to determine a threshold value
distinguishing SNN from controls in the lower limbs (superﬁcial
peroneal and sural nerves). In the upper limbs, the best compro-
mise was a threshold of SAP amplitude530% of the lower limit of
normal that gave 70% sensitivity and speciﬁcity for the ulnar and
median nerves, and 70% sensitivity and 85% speciﬁcity for the
radial nerve in favour of SNN (Fig. 2).
Similar results were observed when comparing independently
unambiguous SNN and likely SNN with controls.
Model testing for diagnostic criteria
for SNN
Among the 85 items tested on the study population for the
elaboration of diagnostic criteria, those with the best positive
discriminative value (highest likelihood ratio+) were ataxia at
onset or main development of the neuropathy, clinical asymmetry
of sensory loss, at least one or two abolished SAP in the upper
limb or the combination of at least one abolished SAP or at least
three SAPs530% of the lower limit of normal in the upper limbs,
and no or less than one motor nerve with abnormal nerve con-
duction studies in the lower limbs. The best negative discriminative
items (lowest likelihood ratio–) were the absence of clinical upper
limb involvement or no large sensory ﬁbre perturbation and a
clinical involvement restricted to lower limbs (Table 2). However,
as none of them reached a discriminative level (likelihood
ratio+410 or likelihood ratio– 50.1), several models of combined
criteria were constructed with the study population. Each model
was elaborated by entering into a logistic regression the variables
included in these models (Table 3). For scoring the different
models, variables in the model were weighted by their respective
logistic regression coefﬁcient. Models 1 and 5 were obtained by
entering in block the items of the Asbury’s and PNSEuronet group
criteria, respectively. Models 2–4 are examples of models built
Table 1 Items differentiating unambiguous and likely SNN in the study population
Unambiguous SNN (%) Likely SNN (%) P-value
Sex (Male/total patients) 31/44 (70.5) 15/34 (44.1) 0.019
Acute–subacute–progressive onset 15–24–5/44 (34.1–54.5–11.4) 4–10–20/34 (11.7–29.4–58.8) 50.0001
Lower limb involvement only at onset 8/44 (18.2) 17/34 (50.0) 0.0036
Four limb involvement at onset 17/44 (38.6) 4/34 (11.8) 0.01
Pain at full development 27/44 (61.4) 12/34 (35.3) 0.0224
Raised CSF protein 25/27 (92.6) 8/21 (38.1) 50.0001
Oligoclonal CSF pattern 7/18 (38.9) 2/20 (10.0) 0.0365
Electroneuromyography with all motor nerves normal 13/42 (30.9) 20/34 (58.8) 0.0148
P-value was determined with the Fisher’s exact test.
The total number of unambiguous and likely SNN on which the statistics was performed for each item corresponds to the denominator. The numerator indicates the
number of cases fulﬁlling the item and the percentage is given into brackets.
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Total cases=134 P-value SNN (%) Controls (%) Sensitivity Speciﬁcity LR+ LR–
Onconeural antibodies 50.0001 31/78 (39.7) 0/56 (0) 0.4 1 1 0.6
Onset
a
Acute 0.0236 19/78 (24.3) 5/56 (8.9) 0.24 0.91 2.73 0.83
Subacute 0.0148 34/78 (43.6) 13/56 (23.2) 0.44 0.77 1.88 0.73
Progressive 50.0001 25/78 (32.0) 37/56 (66.0) 0.32 0.34 0.49 2
Ataxia 50.0001 33/78 (42.3) 5/56 (8.9) 0.42 0.91 4.74 0.63
Asymmetry of sensory loss 0.0067 31/78 (39.7) 10/56 (17.8) 0.4 0.82 2.23 0.73
Including upper limb 50.0001 54/78 (69.2) 15/56 (26.8) 0.69 0.73 2.58 0.42
Including LL 0.001 46/78 (58.9) 48/56 (85.7) 0.59 0.14 0.69 2.87
Clinical manifestations—at full development
Distal upper limb 50.0001 69/78 (88.5) 28/56 (50.0) 0.88 0.5 1.77 0.23
Proximal upper limb 0.0103 9/78 (11.5) 0/56 (0) 0.12 1 1 0.88
Including upper limb 50.0001 73/78 (93.6) 28/56 (50.0) 0.94 0.5 1.87 0.13
Lower limb only 50.0001 5/78 (6.4) 27/56 (48.2) 0.06 0.52 0.13 1.81
Four limbs 50.0001 70/78 (89.7) 28/56 (50.0) 0.9 0.5 1.79 0.21
Face involvement 0.0206 8/78 (10.2) 0/56 (0) 0.1 1 1 0.9
Asymmetry of sensory loss 50.0001 36/78 (46.1) 7/56 (12.5) 0.46 0.88 3.69 0.62
Non length dependent distribution 50.0002 64/78 (82.0) 29/56 (51.8) 0.82 0.48 1.58 0.37
Superﬁcial and deep sensation 0.0023 73/78 (93.6) 42/56 (75) 0.94 0.25 1.25 0.26
Ataxia (upper limb or lower limb) 50.0001 55/78 (70.5) 14/56 (25) 0.71 0.75 2.82 0.39
Dysautonomia 0.0124 17/78 (21.8) 3/56 (5.4) 0.22 0.95 4.07 0.83
CSF
b
Raised protein 0.0052 33/48 (68.8) 10/20 (50.0) 0.69 0.5 1.38 0.63
Raised cell number 0.0002 18/48 (37.5) 0/20 (0) 0.38 1 1 0.63
Oligoclonal pattern 0.023 9/29 (31.0) 0/20 (0) 0.24 1 1 0.76
Nerve conduction study: sensory nerves
Sensory action potential median (mV) 50.0001 2.53 3.34 7.06 5.91 – – – –
Sensory action potential ulnar (mV) 0.0054 1.92 4.78 4.44 3.92 – – – –
Sensory action potential radial (mV) 50.0001 3.69 4.72 12.21 9.04 – – – –
51 Sensory action potential abolished in upper
limb
50.0001 48/78 (61.5) 7/56 (12.5) 0.62 0.88 4.92 0.44
52 Sensory action potential abolished in upper
limb
50.0001 28/78 (35.9) 3/56 (5.4) 0.36 0.95 6.7 0.68
53 Sensory action potential abolished in upper
limb
0.0078 15/78 (19.2) 2/56 (3.6) 0.19 0.96 5.38 0.84
52 Sensory action potential 530% lower limit
of normal upper limb
50.0001 49/78 (62.8) 12/56 (21.4) 0.63 0.79 2.93 0.47
53 sensory action potential 530% lower limit
of normal upper limb
50.0001 29/49 (37.2) 4/56 (7.1) 0.37 0.96 9.25 0.11
51 sensory action potential=0 or 3 sensory
action potential 530% lower limit of normal
upper limb
50.0001 53/78 (67.9) 8/56 (17.8) 0.68 0.86 4.76 0.20
Nerve conduction study: motor nerves
Motor conduction velocities median (ms
–1) 0.0046 50.19 5.69 46.5 8.23 – – – –
Motor conduction velocities ulnar (ms
 1) 0.0128 51.39 6.19 47.43 10.4 – – – –
Compound muscle action potentials Peroneal
(mV)
50.0001 3.48 1.9 1.84 1.84 – – – –
Motor conduction velocities Peroneal ms
–1) 50.0001 43.7 4.97 33.44 12.9 – – – –
Compound muscle action potentials Tibial (mV) 50.0001 6.19 3.49 2.76 2.99 – – – –
Motor conduction velocities Tibial (ms
–1) 50.0001 40.64 4.28 30.44 14.2 – – – –
All motor nerves normal lower limb 0.0001 34/55 (61.2) 8/55 (14.5) 0.62 0.85 4.25 0.45
All motor nerves normal 0.0005 33/76 (43.4) 8/56 (14.3) 0.43 0.86 3.04 0.66
52 abnormal motor nerve lower limb 50.0001 29/76 (38.1) 42/54 (77.8) 0.38 0.22 0.49 2.78
No/minor motor abnormalities 50.0001 49/76 (64.5) 12/56 (21.4) 0.64 0.79 3.01 0.45
Compares the clinical manifestations at onset and at the maximum development of the neuropathy, cerebrospinal ﬂuid and nerve conduction study abnormalities.
P-value was determined with the Fisher exact test for frequency comparison and with the Student t-test for numerical continuous variables. The number of SNN and
controls on which the statistics was performed for each item corresponds to the denominator. The numerator indicates the number of case fulﬁlling the item and the
percentage is given into brackets. For compound muscle action potentials, sensory action potential and motor conduction velocities the mean value_standard deviation is
indicated.
LR=likelihood ratio.
1728 | Brain 2009: 132; 1723–1733 J.-P. Camdessanche ´ et al.Figure 2 ROC curves for the determination of threshold differentiating SNN from other neuropathies for sensory action potentials
expressed as a percentage of the lower limit of normal for the median, ulnar, radial, sural and superﬁcial peroneal nerves.
Table 3 Models of diagnostic criteria
Model Study
population
Study population
Percentage of correct diagnosis with the jackknife method
Test population
Area under ROC
curve (95% CI)
All SNN Unambiguous
SNN
Likely SNN Control Sensitivity Speciﬁcity Likelihood ratio
1 0.78 (0.70–0.86) 51.3 42.8 61.8 85.7 0.92 0.96 23.00
2 0.87 (0.80–0.93) 39.5 33.3 47.0 91.1 0.75 0.84 4.69
3 0.92 (0.85–0.95) 63.8 67.5 59.4 94.5 0.75 0.88 6.25
4 0.89 (0.83–0.94) 86.8 83.3 91.2 79.6 0.92 0.84 5.75
5 0.88 (0.83–0.94) 66.7 77.3 52.9 78.6 0.92 0.84 5.75
6 0.94 (0.90–0.98) 81.6 76.2 88.2 90.7 0.92 1.00 1
7 0.99 (0.98–1.00) 94.7 100.0 88.2 94.4 0.92 1.00 1
Model Model formulation Threshold
1 1.35 NLD distribution+1.95 no or minor motor NCS abnormalities (Asbury’s criteria) 2.6
2 1.23 NLD distribution+2.5 ataxia+2.35 no or minor motor NCS abnormalities 4
3 2.12 upper limb involvement+2.34 ataxia+3.06 normal motor NCS in LL+2.12 4 1 SAP=0 in UL 6
4 2.35 UL involvement+2.62 4 1 SAP=0 in UL+2.22 52 motor nerves with abnormal NCS in LL 4.5
5 1.09 subacute onset – 0.41 paresthesia+0.14 pain+1.16 asymmetry+2.51 Rankin 43+1.64 
UL involvement+1.44 deep sensation involvement – 1.3741 SAP=0 (PNSEuronet group criteria)
3
6 3.1 ataxia+2.04 sensory loss not limited to LL+1.74 asymmetrical distribution of sensory
loss+2.82 41 SAP=0 or 3 SAP530% lower limit of normal in UL+3.08 52 motor nerves with
abnormal NCS in LL
6.5
7 Model 6+22.26 onconeural antibody/cisp – 22.13 biology or electroneuromyography excluding SNN 6.5
Different tested models are showed with their area under the ROC curve + 95% CI and the percentage of correct diagnosis after jackknife on the study population and
their sensitivity, speciﬁcity and likelihood ratio on the test population.
The different models are described as a mathematical formula where each clinical or electrophysiological item must be coded as 1 or 0 according as to whether
the condition is fulﬁlled or not and multiplied by the logistic regression coefﬁcient. The threshold differentiating patients as having or not having SNN is determined by
the ROC curve.
NLD=non-length-dependent distribution, UL=upper limb, LL=lower limb, NCS=nerve conduction study, Cisp=cisplatin treatment.
NLD or asymmetrical distribution and UL or LL involvement correspond to the clinical distribution of sensory loss.
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the best likelihood ratio+ or likelihood ratio–. Finally, Model 6 was
provided by the stepwise logistic regression after entering all the
items having the best likelihood ratio+ or likelihood ratio . Model
7 corresponded to Model 6 with the adjunction of two further
variables corresponding to items obtained after the initial workup
and (i) making the diagnosis of SNN unambiguous (detection of
onconeural antibodies or presence of a context of cisplatin treat-
ment) or (ii) excluding SNN (presence of anti-MAG or anti-disialosyl
antibodies, nerve conduction studies indicating demyelination, a
context of diabetes mellitus, treatment-induced toxicity other than
cisplatin or B12 deﬁciency).
In the study population, the jackknifed Asbury’s criteria gave
wholly poor results while the PNSEuronet group criteria correctly
identiﬁed 77.3% of unambiguous SNN (84.8% in the paraneo-
plastic group), but only 52.9% of patients in the likely group.
The best results were obtained with Model 6 which correctly
identiﬁed 81.6% of the SNN patients and 90.7% of controls.
Adjunction of contextual items improved the correctness of the
diagnosis in the unambiguous and control groups.
In the small external prospective test population, Model 1 had
good accuracy when compared with the clinician diagnosis
(likelihood ratio+=23), but Model 6 was superior as the Asbury’s
criteria detected as a positive case a patient initially diagnosed
as having SNN, a diagnosis ruled out later by a complementary
ENMG and biological investigations and excluded by Model 6.
Finally, considering Model 6 as the best one in both the jack-
knifed study and test population, and taking into account the
interest of the initial biological and electrophysiological workup,
we propose the following easy-to-use score form for the diagnosis
of SNN in which the coefﬁcient of each variable is the logistic
regression coefﬁcient:
A In a patient with a clinically pure sensory neuropathy a diagnosis
of SNN is considered as possible if score 46.5
Yes Points
a—Ataxia in the lower or upper limbs at onset
or full development
œ +3.1
b—Asymmetrical distribution of sensory loss at
onset or full development
œ +1.7
c—Sensory loss not restricted to the lower
limbs at full development
œ +2.0
d—At least 1 SAP absent or 3 SAP 530% of
the lower limit of normal in the upper limbs,
not explained by entrapment neuropathy
œ +2.8
e—Less than two nerves with abnormal motor
nerve conduction studies in the lower limbs
œ +3.1
If 46.5, a diagnosis of SNN is possible Total
B A diagnosis of SNN is probable if the patient’s score is 46.5
and if:
1. The initial workup does not show biological perturbations or
ENMG ﬁndings excluding SNN and
2. The patient has one of the following disorders: onconeural
antibodies or a cancer within 5 years (Graus et al., 2004),
cisplatin treatment, Sjo ¨gren’s syndrome (Vitali et al., 2002).
3. Or MRI shows high signal in the posterior column of the spinal
cord
C A diagnosis of SNN is deﬁnite if dorsal root ganglia degeneration
is pathologically demonstrated although dorsal root ganglia
biopsy is not recommended.
Discussion
Because of the frequent absence of reference standard, diagnostic
criteria of peripheral neuropathies have often been established on
expert consensus raising the question of whether methodologies
independent of subjective appreciations would be more pertinent.
However, this remains a difﬁcult challenge because none of these
methods is free of potential bias especially in the selection of the
reference and control populations. Here, to limit bias due to selec-
tion of diagnostic criteria on a preconceived representation of
what a SNN should be, we used logistic regression to identify
clinical and electrophysiological items that may accurately identify
SNN from other sensory neuropathies. In the absence of deﬁnite
proof of dorsal root ganglia involvement or other gold standard,
we provisionally classiﬁed the SNN patients in the study population
according to two levels of certitude for the diagnosis of SNN. The
ﬁrst was based on the fair demonstration in the scientiﬁc literature
that the underlying disorder results from a primary degeneration
of sensory neurons in dorsal root ganglia (e.g. paraneoplastic
cases) and the second, on the absence of ambiguity concerning
the main lesion site when several forms of neuropathy may be
associated with the said disorder (Sjo ¨gren’s syndrome or HIV
infection for example). Despite this distinction, the general clinical
and electrophysiological pattern was similar in unambiguous and
likely SNN. This is an important point since it ﬁrst shows that a
general pattern of SNN can be established independently of the
underlying disorder and second that patients here provisionally
classiﬁed as likely SNN and who mostly conformed to the
Asbury’s criteria have a great chance to actually have developed
a lesion in the dorsal root ganglia and hence that the whole study
population could be used to establish diagnostic criteria.
Selection of the control population is another important meth-
odological issue since it determines the negative reference against
which the SNN population was compared. Here, we selected
patients with neuropathies that can be without doubt (e.g.
demyelinating neuropathy or mononeuritis multiplex) or likely
(e.g. distal axonal sensory neuropathy) classiﬁed as non-SNN.
These cases were selected not for the relative frequency of their
neuropathy in our general population of neuropathy but to
represent an as large as possible panel of the different patterns
of sensory neuropathies.
By comparing SNN to other sensory neuropathies several statis-
tically signiﬁcant distinctive features appeared. Although we
cannot rule out that some of them may have been selected by
chance, the whole pattern of a predominantly distal sensory neu-
ropathy with almost universal upper limb involvement extending
sometimes to the face or trunk and frequent alteration of deep
sensation conforms to what has been previously reported
(Dalakas, 1986; Grifﬁn et al., 1990; Windebank et al., 1990;
Sobue et al., 1993; Mori et al., 2005). However, behind this
general presentation we observed variants that were not speciﬁc
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proposed set of diagnostic criteria. These include forms with
only patchy sensory loss, mild electrical motor nerve abnormalities
and predominant small ﬁbre or isolated lower limb involvement.
The existence of SNN restricted to small sensory neurons is still
debated. It has been reported with Sjo ¨gren’s syndrome (Mori
et al., 2003; Chai et al., 2005), coeliac disease (Brannagan et
al., 2005) or idiopathic cases (Gorson et al., 2008), but has not
been demonstrated yet by an examination of dorsal root ganglia.
In this study, all the patients with a clinical small ﬁbre neuropathy
had abnormal SAP indicating an associated involvement of large
neurons.
An electrophysiological pattern common to acquired SNN
could also be established. Diffuse abnormal SAP recording was a
universal feature but with important individual variations. Abolition
of SAP in the upper limbs was frequent but not universal and a
reduction of SAP 530% of the lower limit of normal in at least
three nerves in the upper limbs, especially in the radial nerve
was more discriminative. Mild motor nerve abnormalities were
not uncommon particularly with paraneoplastic disorders
(Camdessanche et al., 2002). These results contrast with studies
that stressed the severity of sensory nerve abnormalities and the
almost absence of motor nerve perturbations in SNN possibly
because patients have been selected with too restrictive criteria
(Dalakas, 1986; Windebank et al., 1990; Chalk et al., 1992;
Lauria et al., 2003). Extension of electrophysiological abnormalities
to motor ﬁbres without any clinical counterpart probably results
from a diffusion of the pathological process beyond sensory
ganglia into the peripheral nerves. This is in keeping with the
ﬁnding of inﬂammatory changes in peripheral nerves of patients
with demonstrated SNN (Antoine et al., 1998; Mori et al., 2005).
Finally, the only distinctive features between unambiguous and
likely SNN concerned onset and CSF. Both were linked to the
nature of the process underlying the neuropathy and could not
be used for the elaboration of diagnostic criteria.
As peripheral neuropathy is a frequent cause of referral, there is
a need for easy-to-use criteria that can differentiate SNN from
other neuropathies and be sensitive enough to pick up the unusual
variants. To be utilized in non-specialized centres, these criteria
must also draw on materials available on ﬁrst-hand investigation
such as clinical examination and electrophysiological study, and so
the Asbury’s criteria was built (Asbury, 1987; Asbury and Brown,
1990). However, we found that although patients with likely SNN
mostly conform to the Asbury’s criteria, these criteria had low
accuracy because ﬁrst, a non-length-dependent distribution is
not speciﬁc enough as it also occurs with other neuropathies
such as B12 deﬁciency, sensory variants of, or neuropathies due
to vasculitis or leprosy; and second, a signiﬁcant but limited
electrophysiological motor nerve involvement does not rule out a
diagnosis of SNN. The PNSEuronet group criteria were accurate in
patients with paraneoplastic SNN but were not reliable with other
forms of SNN. Among the different models tested in this study,
we selected the one built by the stepwise logistic regression that
only used ﬁrst-hand clinical data and ENMG recording of motor
and sensory nerve conduction in the four limbs with at least a
study of three sensory nerves in the upper limbs. This model
was sensitive with both deﬁnite and possible SNN in the jackknifed
study population where it identiﬁed the unusual forms of SNN
and gave fairly good results in the external test population. In
particular, it excluded cases for which the clinician diagnosis was
initially hesitant. In addition it was effective in excluding non SNN
sensory neuropathies. However, the perfect speciﬁcity of this
model in the test population probably results from the relative
small size of the sample that likely did not include all the possible
presentations. Validation on a larger population of patients
originating from different centres will be needed.
The patients detected by these criteria should be investigated
for the usual aetiologies of SNN. This set of criteria does not take
into account items that can guide to speciﬁc underlying causes.
However, an acute or subacute onset and an inﬂammatory CSF
strongly argues for a paraneoplastic origin while chronic evolution
or normal CSF favours the hypothesis of a dysimmune or idio-
pathic SNN (Chalk et al., 1992; Dalakas, 1986; Graus et al.,
2001). The diagnostic criteria speciﬁcally built for paraneoplastic
disorders (Graus et al., 2004) or Sjo ¨gren’s syndrome (Vitali et al.,
2002) can be used for the aetiological diagnosis of SNN. Thus, in
a patient with possible SNN according to clinical and electrophy-
siological data, a context of cisplatin treatment, detection of
onconeural AB, occurrence of cancer in a short delay within the
evolution of the neuropathy, diagnosis of an HIV infection or
Sjo ¨gren’s syndrome can be considered as evidences of probable
SNN. The absence of diagnosis items that rule out SNN such as
demyelinating features on the ENMG, or biological perturbations
may also contribute to a probable diagnosis of SNN. However,
this may be modulated since it cannot be excluded that some
conditions to date considered as not associated with SNN may
in the future prove to be a cause of ganglionopathy as it has
been for example suggested with diabetes mellitus (Kishi et al.,
2002). Here, we restricted the deﬁnite level of diagnosis to cases
for which there is a pathological examination of dorsal root
ganglia which is at present the only way to demonstrate neuron
degeneration (Grifﬁn et al., 1990; Colli et al., 2008). However, in
want of a still unavailable method of non-traumatic exploration of
dorsal root ganglia in living people, this level will seldom be
reached as biopsy of these cells cannot be recommended as a
routine examination.
Other markers have been proposed for the diagnosis of SNN.
Spinal cord MRI may be used as a proxy of large sensory neuron
degeneration. In our series, it was disappointing, possibly for
technical reasons. Although it should be underlined that T2-high
signal in the dorsal column is not speciﬁc of SNN as it occurs in
B12 deﬁciency (Lauria et al., 2000), its presence may be a sup-
portive argument and was considered as such in the proposed
criteria. SEPs may also help to demonstrate an involvement of
both the central and peripheral sensory pathway but the rapid
degeneration of the peripheral process is a strong limitation to
their interest.
Finally, skin biopsy has been used to demonstrate a non-length-
dependant distribution of small ﬁbre loss for the diagnosis of SNN
(Lauria et al., 2001) and has recently been proposed for the inves-
tigation of patients with pure small ﬁbre neuropathy (Sommer and
Lauria, 2007). However, skin biopsy cannot presently be
considered as a routine exam for the investigation of patients
with sensory neuropathy, since it needs to be performed in
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this method in our criteria. When applied to the patients reported
by Gorson et al. (2008) as having a painful neuropathy possibly
due to a SNN restricted to small sensory neurons and diagnosed
on skin biopsy the selected model gave positive results in only
3/23 of these patients. Skin biopsy can be helpful in difﬁcult
cases. Whether it may be used as an equivalent of the ENMG
when the latter is normal needs speciﬁc investigations.
In conclusion, the method used here was for the ﬁrst time
applied to the elaboration of diagnostic criteria in a group of
peripheral neuropathy for which there is yet no validated gold
standard. Our study conﬁrms that despite their different origins,
acquired SNN have a common clinical and electrophysiological
pattern distinctively different from other sensory neuropathies
despite the existence of variants. With statistical methods powered
for determination of diagnostic accuracy, we evaluated several
sets of diagnostic criteria applicable in routine clinical care by
any clinician as they rely only on clinical examination and
ENMG. We found that one set had a good discriminative value
and may be useful for the diagnosis of patients with sensory
neuropathy.
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